Physician profile
Timothy J Doyle
NPI 1073540381
$6,332.59
in general payments reported to CMS, 2019-2025
56 companies · $731 in 2025
The $731 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $900 · 2021: $717 · 2022: $905 · 2023: $1,065 · 2024: $1,003 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $723.03 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $657.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $637.18 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $492.08 | 2021-2025 | Vraylar, Dalvance, Ubrelvy |
| Pfizer INC. | $384.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.45 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $280.48 | 2019-2021 | |
| Abbott Laboratories | $254.73 | 2019-2025 | Freestyle Libre 3, Jot Dx |
| Astellas Pharma US INC | $240.27 | 2020-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $219.64 | 2020-2022 | |
| Allergan, INC. | $151.22 | 2019-2020 | |
| Amgen INC. | $127.73 | 2021-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $117.10 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.69 | 2019-2022 | |
| Avinger INC. | $91.37 | 2023 | Pantheris |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $89.43 | 2025 | Fibroscan |
| Exact Sciences Corporation | $84.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $84.15 | 2020-2025 | |
| Abiomed | $74.53 | 2025 | |
| Janssen Pharmaceuticals, INC | $74.50 | 2022-2023 | Xarelto |
| Glaxosmithkline, LLC. | $70.38 | 2019-2023 | Trelegy Ellipta |
| Edwards Lifesciences Corporation | $63.45 | 2022-2025 | Sapien 3 Ultra Resilia |
| Baxter Healthcare | $62.74 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Mylan Specialty L.P. | $61.32 | 2024 | Yupelri |
| Viatris Specialty LLC | $61.15 | 2025 | Yupelri |
| Amarin Pharma, INC. | $59.95 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $57.80 | 2023-2024 | Rexulti |
| Endogastric Solutions, INC | $51.00 | 2024 | Esophyx |
| Inspire Medical Systems, INC. | $44.61 | 2024-2025 | Inspire |
| Genentech USA, INC. | $40.47 | 2019-2020 | |
| Noven Therapeutics, LLC | $36.85 | 2023 | Xelstrym, Secuado |
| Sumitomo Pharma America, INC. | $36.52 | 2024-2025 | Gemtesa |
| Antares Pharma, INC. | $34.13 | 2020-2021 | |
| Shield Therapeutics INC | $33.07 | 2023-2024 | Accrufer |
| Medtronic, INC. | $30.11 | 2023-2025 | Intellis Adaptivestim, Venaseal |
| Jazz Pharmaceuticals INC. | $24.62 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.83 | 2022 | |
| Dynavax Technologies Corporation | $22.39 | 2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $21.30 | 2022 | |
| Orexo US, INC. | $20.23 | 2019 | |
| Boston Scientific Corporation | $19.15 | 2024 | |
| Corcept Therapeutics | $19.06 | 2025 | Korlym |
| Bausch Health US, LLC | $18.94 | 2020 | |
| Biogen, INC. | $18.41 | 2020 | |
| Avanir Pharmaceuticals, INC. | $18.19 | 2019 | |
| Nevro Corp. | $17.54 | 2023 | Senza |
| Axsome Therapeutics, INC. | $16.79 | 2024 | Auvelity |
| Sanofi Pasteur INC. | $16.58 | 2020 | |
| Currax Pharmaceuticals LLC | $15.78 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $15.71 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.86 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $14.59 | 2023 | Quviviq |
| Radius Health, INC. | $13.77 | 2020 | |
| Braeburn INC. | $13.66 | 2024 | Brixadi |
| Shire North American Group INC | $13.00 | 2019 | |
| Acerus Pharmaceuticals Corporation | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.